Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040914 | 0.93 | NR1H2 (0.38) | HTR6BDKRB1MAP3K7IRAK1IRAK4 | |
| SCHEMBL3047662 | 0.92 | NR1H2 (0.37) | NR1H2ALDH1A1KMT2A | |
| SCHEMBL3039560 | 0.92 | NR1H2 (0.40) | NR1H2 | |
| SCHEMBL3049978 | 0.91 | NR1H2 (0.39) | BDKRB1NR1H2 | |
| SCHEMBL3047451 | 0.90 | NR1H2 (0.40) | HTR6NR1H2 | |
| SCHEMBL3040414 | 0.89 | NR1H2 (0.34) | BDKRB1NR1H2ALDH1A1 | |
| SCHEMBL3039690 | 0.89 | NR1H2 (0.40) | BDKRB1NR1H2 | |
| SCHEMBL3045896 | 0.88 | MEN1 (0.34) | NR1H2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3044144 | 0.88 | NR1H2 (0.33) | BDKRB1NR1H2 | |
| SCHEMBL3042182 | 0.88 | NR1H2 (0.40) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | HTR6 360/4885BDKRB1 2607/4885MAP3K7 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.